What is the difference between a user profile and an account on a simulation training platform?

On the one hand, “ClinCaseQuest” is a platform for trainings and clinical cases, and on the other hand – a specialized social network for the medical community for discussing clinical cases and exchanging experience between doctors.

When you register on the Platform, your account and social profile are automatically created.

• Account is more related to the learning activities of the user, demonstrates their learning progress, successes and achievements in learning.
• Social profile is related to opportunities for communication, networking with colleagues, participation in discussions of clinical cases, exchange of experience between doctors.

Currently, the simulation training platform “ClinCaseQuest” operates in three languages:

English https://clincasequest.hospital/

Ukrainian https://clincasequest.academy/

Russian https://clincasequest.org/

You can log in to any language platform with your own login and password, which are universal for all three simulation learning platforms (see the “How to access the Platform” instruction.)

All platforms form a single social communication network so that you can choose a convenient language for learning and at the same time have opportunities for international communication.

In each language platform you have a training account, separate trainings for which you register and in which you undergo training. You currently have three training accounts in each of the language platforms, some trainings you can take in one language, other trainings in another language, but if you plan to buy a paid subscription for the entire database of clinical cases – choose the most convenient language for learning and get annual access.

Your social profile, which is created for you during registration, is the same for all three platforms, you have a single Platform and user news feed. Thus, the account is associated with your learning in a convenient language in the appropriate language platform, whereas the user’s profile is associated with opportunities to communicate and share experience with colleagues, presenting your own professional development.

Register on our website right now to have access to more learning materials!

Register

Charlson Comorbidity Index (CCI) Online Calculator

May 10, 2023

Charlson Comorbidity Index predicts 10-year survival in patients with multiple comorbidities.

Loading...

Email (indicate if you want the results to be sent to your email)

Date of assessment

---

Age *

<50 years

50–59 years

60–69 years

70–79 years

≥80 years

Myocardial infarction *

History of definite or probable MI (EKG changes and/or enzyme changes)

No

Yes

Congestive heart failure *

Exertional or paroxysmal nocturnal dyspnea and has responded to digitalis, diuretics, or afterload reducing agents

No

Yes

Peripheral vascular disease *

Intermittent claudication or past bypass for chronic arterial insufficiency, history of gangrene or acute arterial insufficiency, or untreated thoracic or abdominal aneurysm (≥6 cm)

No

Yes

Cerebrovascular accident or Transient ischemic attack *

History of a cerebrovascular accident with minor or no residua and transient ischemic attacks

No

Yes

Dementia *

Chronic cognitive deficit

No

Yes

Chronic obstructive pulmonary disease *

No

Yes

Connective tissue disease *

No

Yes

Peptic ulcer disease *

Any history of treatment for ulcer disease or history of ulcer bleeding

No

Yes

Liver disease *

Severe = cirrhosis and portal hypertension with variceal bleeding history, moderate = cirrhosis and portal hypertension but no variceal bleeding history, mild = chronic hepatitis (or cirrhosis without portal hypertension)

None

Mild

Moderate to severe

Diabetes mellitus *

None or diet-controlled

Uncomplicated

End-organ damage

Hemiplegia *

No

Yes

Moderate to severe chronic kidney disease *

Severe = on dialysis, status post kidney transplant, uremia, moderate = creatinine >3 mg/dL (0.27 mmol/L)

No

Yes

Solid tumor *

None

Localized

Metastatic

Leukemia *

No

Yes

Lymphoma *

No

Yes

AIDS *

No

Yes

---

Charlson Comorbidity Index

10-year survival

Details:

Reset

* Required

VariablePointsAge <50…

Read More

Multiple Myeloma Diagnostic Criteria – Online Calculator

February 5, 2023

Loading...

Email (indicate if you want the results to be sent to your email)

Date of assessment

---

≥1 of the following (A or B)

*

A. Clonal bone marrow plasma cells ≥10%

B. Biopsy-proven bony or extramedullary plasmacytoma

≥1 myeloma defining event (C1 or C2)

• C1. End organ damage attributable to underlying plasma cell disorder (≥1 of the following): *

o Hypercalcemia (Serum calcium >1 mg/dL (>0.25 mmol/L) higher than upper limit of normal or >11 mg/dL (>2.75 mmol/L))

o Renal insufficiency (Creatinine clearance<40 mL per min or serum creatinine >2 mg/dL (177 μmol/L))

o Anemia (Hemoglobin >2 g/dL (20 g/L) below lower limit of normal

o Bone lesions (≥1 osteolytic lesion on skeletal x-ray

• C2. ≥1 of the following biomarkers of malignancy: *

o Clonal bone marrow plasma cells ≥60%

o Involved:uninvolved sFLC ratio ≥100

o >1 focal lesion on MRI

---

Result

Diagnostic result Negative. Not positive for multiple myeloma by IMWG criteria

Diagnostic result Positive for multiple myeloma by IMWG criteria

Details:

Reset

* Required

For Multiple Myeloma Diagnostic Criteria assessment necessary to provide selection of the…

Read More

Revised Multiple Myeloma International Staging System (R-ISS) Online Calculator

January 17, 2023

Revised Multiple Myeloma International Staging System (R-ISS) – prognostication tool for myeloma patients based on…

Read More

Multiple Myeloma International Staging System (ISS) Online Calculator

January 16, 2023

Multiple Myeloma International Staging System (ISS) prognosticates the severity of multiple myeloma based on routinely…

Read More

SAVED VTE Score

January 11, 2023

SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulators. [ezfc…

Read More

IMPEDE VTE Score

January 11, 2023

IMPEDE score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulators. [ezfc…

Read More